Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Erion Dobi"'
Autor:
Chloé Drozd, Elsa Curtit, Quentin Jacquinot, Charlène Marquine, Laura Mansi, Loïc Chaigneau, Erion Dobi, Julien Viot, Guillaume Meynard, Marie-Justine Paillard, Morgan Goujon, Pauline Roux, Dewi Vernerey, Valérie Gillet, Hubert Bourdin, Silvio Galli, Nathalie Meneveau, Fabienne Mougin
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)
Abstract Background Up to 70% of breast cancer patients report symptoms of insomnia during and after treatment. Despite the ubiquity of insomnia symptoms, they are under-screened, under-diagnosed and poorly managed in breast cancer patients. Sleep me
Externí odkaz:
https://doaj.org/article/5473dfa5db4749b08b82dda664fb277d
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2− early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures
Externí odkaz:
https://doaj.org/article/fb403b3f72cf4ec7a11eabb6e2d69679
Autor:
Quentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, Malika Bouhaddi, Pauline Roux, Bruno Degano, Marion Chatot, Elsa Curtit, Laura Mansi, Marie-Justine Paillard, Fernando Bazan, Loïc Chaigneau, Erion Dobi, Guillaume Meynard, Dewi Vernerey, Xavier Pivot, Fabienne Mougin
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
BackgroundTrastuzumab is used, alone or in conjunction with standard chemotherapy, to treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab. can lead to cardiotoxicity. Physical exercise is a safe and effective sup
Externí odkaz:
https://doaj.org/article/b99f6aa41f744bdf96b74aa0e763ad8d
Autor:
Fabien Calcagno, Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, François Kleinclauss, Xavier Pivot, Antoine Thiery-Vuillemin
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2013, Iss 7, Pp 1-12 (2012)
Externí odkaz:
https://doaj.org/article/2c07c35110464a898a790e14bfb88209
Autor:
Fabien Calcagno, Thierry Nguyen, Erion Dobi, Cristian Villanueva, Elsa Curtit, Stefano Kim, Philippe Montcuquet, François Kleinclauss, Xavier Pivot, Antoine Thiery-Vuillemin
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 7 (2013)
Prostate cancer (PC) is one of the most common cancers and is a leading cause of death. Its initial growth is dependent on androgens; most patients show an initial response to hormonal therapy but will experience disease progression when PC becomes r
Externí odkaz:
https://doaj.org/article/3849a954fffa43ac928ab014ccfde66b
Autor:
Christophe Borg, Franck Bonnetain, Olivier Adotevi, Lise Queiroz, Julie Leger, Anthony Gonçalves, Serge Fratte, Olivier Bouché, Stefano Kim, Yann Godet, Franck Monnien, François Ghiringhelli, Erion Dobi, Thierry Lecomte, Dewi Vernerey, Marine Jary
Background: Baseline prognostic biomarkers stratifying treatment strategies in first-line metastatic colorectal cancer (mCRC) are lacking. Angiopoietin-2 (Ang-2) is proposed as a potential biomarker in several cancers. We therefore decided to establi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5635434c6f2fbb30725f4ad69f27c812
https://doi.org/10.1158/1055-9965.c.6516264.v1
https://doi.org/10.1158/1055-9965.c.6516264.v1
Autor:
Christophe Borg, Franck Bonnetain, Olivier Adotevi, Lise Queiroz, Julie Leger, Anthony Gonçalves, Serge Fratte, Olivier Bouché, Stefano Kim, Yann Godet, Franck Monnien, François Ghiringhelli, Erion Dobi, Thierry Lecomte, Dewi Vernerey, Marine Jary
Supplementary Methods, Table 1. Supplementary methods: - Ang-2 plasma sample measurement - Statistical analysis interpretation Supplementary table 1: - Cox Univariate analyses for OS prediction with and without the stratified approach (sensitivity an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed84236dbd58c6cfae877467b1cefc6
https://doi.org/10.1158/1055-9965.22438212
https://doi.org/10.1158/1055-9965.22438212
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX® test was designed for ER+/HER2- early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score® (RS®). RS® measures th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1067abffda23dae2694a335b0cc9c45
https://doi.org/10.21203/rs.3.rs-677106/v1
https://doi.org/10.21203/rs.3.rs-677106/v1
Autor:
Zohair Selmani, Chloé Molimard, Alexis Overs, Fernando Bazan, Loic Chaigneau, Erion Dobi, Nathalie Meneveau, Laura Mansi, Marie-Justine Paillard, Guillaume Meynard, Julien Viot, Marie-Paule Algros, Christophe Borg, Jean-Paul Feugeas, Xavier Pivot, Jean-Luc Prétet, Elsa Curtit
Publikováno v:
Scientific reports. 12(1)
Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2− early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c3f89f5172c0f289e75f94b19cd170a
https://pubmed.ncbi.nlm.nih.gov/35256657
https://pubmed.ncbi.nlm.nih.gov/35256657
Autor:
Bernard Royer, Elsa Curtit, C. Villanueva, N. Menneveau, L. Mansi, Loic Chaigneau, Fernando Bazan, M.-J. Paillard, G. Meynard, Erion Dobi, Xavier Pivot
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-6 (2019)
BMC Cancer
BMC Cancer
Background Infusion of high-dose intravenous methotrexate (MTX) has been demonstrating to penetrate the blood-brain barrier. The aim of this present study was to assess the efficacy and safety of high dose MTX in patients with central nervous system
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf53ae1f4b742c21e0d42515d685a56f
http://link.springer.com/article/10.1186/s12885-019-6228-6
http://link.springer.com/article/10.1186/s12885-019-6228-6